Novel agents in the treatment of atherosclerosis

References

• DUNNIGAN MG: The problem with cholesterol Br. Med. J. (1993) 306:1355.
   Google Scholar
• GILES WH, ANDA RF, JONES DH, SERDULA MK, MERRIT RK, DE STEFANO F: Recent trends in the identification and treatment of high blood cholesterol by physicians. J. Am. Med. Assoc. (1993) 269:1133.
   Web of Science ®Google Scholar
• NIH CONSENSUS DEVELOPMENT PANEL ON TRIGLYCERIDE, HIGH-DENSITY LIPOPROTEIN AND CORONARY HEART DISEASE: Triglyceride, high-density lipoprotein and coronary heart disease. J. Am. Med. Assoc. (1993) 269:505.
   PubMed Web of Science ®Google Scholar
• RUBINS HB, ROBINS SJ, IWANE MK, ET AL.: Rationale and design of the Department of Veterans high-density lipoprotein cholesterol intervention trial (111T) for sec-ondary prevention of coronary artery disease in man with low high-density lipoprotein cholesterol and de-sirable low-density lipoprotein cholesterol Am. J. Cardiol. (1993) 71:45.
   Google Scholar
• DAVEY SMITH G, SONG F, SHELDON TA: Cholesterol lowering and mortality: the importance of considering Initial level of risk. Br. Med. J (1993) 306:1367.
   PubMed Web of Science ®Google Scholar
• OLIVER M: New horizons in the pathogenesis of coro-nary heart disease. Eur. J. Clin. Invest. (1992) 22:761.
   PubMed Web of Science ®Google Scholar
• FEARS R: Future developments in drug therapy. In: Lipoproteins in Health and Disease Betteridge DJ, Illingworth DR, Shepherd J (Eds), Edward Arnold, Sevenoaks, 1994, In press.
   Google Scholar
• SHEPHERD J: Drug therapy for atherosclerosis. Biochem. Soc. Transact. (1993) 21:635.
   PubMed Web of Science ®Google Scholar
• FEARS R: Mode of action of lipid lowering drugs. In: Lipoprotein Metabolism Shepherd J (Ed), Bailliere Tindall, London, 1087, 727.
   Google Scholar
• BARD JM, FRUCHART JC: Triglyceride-rich particles, high-density lipoprotein and their pharmacologicalmodulation. Biochem. Soc. Transact. (1993) 21:647.
   PubMed Web of Science ®Google Scholar
• PARRA F1.1, ARVEILER D, EVANS AE, ET AL: A case-controlstudy of lipoprotein particles in two populations at contrasting risk for coronary heart disease. Arterioscle-rosis and Thrombosis (1992) 12:701.
   PubMed Web of Science ®Google Scholar
• WOOLF N: The atherosclerotic arterial wall. Biochem. Soc. Transact. (1993) 21:639.
   PubMed Web of Science ®Google Scholar
• DAVIES MJ, WOOLF N: Atherosclerosis: what is it and why does it occur? Br. Heart J. (1993) 69(Suppl.):S3.
   Google Scholar
• BROWN BG, ZHAO XQ, SACCO DE, ALBERS B: Lipid lowering and plaque regression. Circulation (1993) 87:1781.
   PubMed Web of Science ®Google Scholar
• BORER JS: Drugs for atherosclerosis and for ischaemia: Have the indications for approval merged? In:Atherosclerosis and Drug Development for Ischaemic Heart Disease Borer J (Ed) J Clin. Pharmacol. (1992) 32:848.
   Google Scholar
• WU H, MOULTON KS, GLASS C.K: Macrophage scavengerreceptors and atherosclerosis. Trends Cardiovasc. Med. (1992) 2:220.
   PubMed Web of Science ®Google Scholar
• KRIEGER M, ACTON S, ASHKENAS J, ET AL.: Molecularflypaper, host defense and atherosclerosis./ Bid. Chem. (1993) 268:4569.
   Google Scholar
• ROSS R: The pathogenesis of atherosclerosis: a perspec- five for the 1990s. Nature (1993) 362:801.
   PubMed Web of Science ®Google Scholar
• WITZTUM JL: Role of oxidised low density lipoprotein In atherogenesis. Br. Heart J. (1993) 69:(Suppl.):S12.
   Google Scholar
• JACKSON EL: Antioxidants for the treatment and pre-vention of atherosclerosis. Biochem. Soc. Transact. (1993) 21:650.
   PubMed Web of Science ®Google Scholar
• FARUQI RM, DICORLETO PE: Mechanisms of monocyterecruitment and accumulation. Br. Heart J. (1993) 69(Suppl.):S19.
   Google Scholar
• YUE TL, MCKENNA PJ, LYSKO PG, RUFFOLO RR, FEUER-OSTEIN GZ: CarvedRol, a new antihypertensive, preventsoxidation of human low density lipoprotein by macro- phages and copper. Atherosclerosis (1992) 97:209.
   PubMed Web of Science ®Google Scholar
• STEIN13ERG D: Antioxidants in the prevention of human atherosclerosis. Circulation (1992) 85:2337.
   PubMedGoogle Scholar
• SOBEL S: Regulatory issues relating to cholesterol low-ering drugs: Where do we stand? In: Atherosclerosis and Drug Development forlscbaemic Heart Disease Borer J (Ed), J. Clin. PharmacoL (1992) 32:848.
   PubMedGoogle Scholar
• ANDALIBI A, LIAO F, IMES S, FOGELMAN AM, LUSIS AJ: Oxidized lipoproteins influence gene expression bycausing oxidative stress and activating the transcrip-tion factor NF-icB. Biochem. Soc. Transact. (1993) 21:651.
   PubMed Web of Science ®Google Scholar
• COLLINS T: Biology of disease. Endothelial nuclear fac- tor - KB and the initiation of the atherosclerotic lesion. Lab. Invest. (1993) 68:499.
   Google Scholar
• LOSCALZO J: The induction of cellular interactions in atherogenesis and their modulation. Biochem. Soc. Transact. (1993) 21:656.
   PubMed Web of Science ®Google Scholar
• RUDD MA, RABBANI LE, GEORGE D, ET AL.: The effects of macrophage colony-stimulating factor on tissue cho-lesterol and cholesteryl ester. Clin. Res. (1992) 40:292A.
   Google Scholar
• LAWN RM, WADE DP, HAMMER RE, ET AL.: Atherogenesis in transgenic mice expressing human apolipoprotein (a). Nature (1992) 360:670.
   Google Scholar
• GRAINGER DJ, KIRSCHENLOHR JL, METCALFE JC, ET AL.: Proliferation of human smooth muscle cells promoted by lipoprotein (a). Science(1993) 260:1655.
   Google Scholar
• ANON: Ciprostene - a breakthrough in restenosis pre-vention? Scrip (1993) 1806:26.
   Google Scholar
• EVANS MA, ASSENDER JW, NEWBY AC: Selective inhibi-tors of protein kinase Care potent inhibitors of vascular smooth muscle proliferation. Br. Heart J. (1992) 68:109.
   Google Scholar
• SOUTHGATE KM, DAVIES M, BOOTH RFG, NEWBY AC: Involvement of extracellular-matrix-degrading metal-loproteinases in rabbit aortic smooth-muscle cell pro-liferation. Biocbem. (1992) 288:93.
   PubMed Web of Science ®Google Scholar
• BENNETT MR, EVAN GI, NEWBY AC: Role of c-myc proto-oncogene expression in inhibition of vascular smooth muscle cell proliferation. Br. Heart J. (1992) 68:93.
   Google Scholar
• HUTCHINSON HG, SHI Y, SIGMAN S, ET AL.: Inhibition of human vascular smooth mus de cell proliferation using c-myc antisense oligonucleotides. Circulation (1992) 86:1–226.
   Google Scholar
• SIMONS M, EDELMAN ER, DEKEYSER JL, LANGER R, ROSE-NBERG RD: Antisense c-myb oligonudeotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature (1992) 359:67.
   PubMed Web of Science ®Google Scholar
• SUCKLING ICE: Emerging strategies for the treatment of atherosclerosis as seen from the patent literature. Bio-chem. Soc. Transact. (1993) 21:660.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ CJ, VALENTE AJ, SPRAGUE EA, ET AL.: Atherosclerosis. Potential targets for stabilization and regression. Circulation (1992) 86:111–117.
   Google Scholar
• Gorr° AM: Dyslipidemia and atherosclerosis. A fore-cast of pharmaceutical approaches. Circulation (1993) 87:111–54.
   Google Scholar
• CLELAND JGF, KRIKLER DM: Modification of atherosclerosis by agents that do not lower cholesteroL Br. Heart J. (1993) 69(Suppl.)554.
   Google Scholar
• PICICERING JG, BACHA PA, WEIR L, ET AL., Prevention of smooth muscle cell outgrowth from human atherosclerotic plaque by a recombinant cytotoxin spe-cific for the epidermal growth factor receptor. J. Clin. Invest., (1993) 91:724.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI S, OIDA K, FUJIWARA R, ET AL.: Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells In culture. J. Cardiovasc. PbarmacoL (1992) 20:900.
   Google Scholar
• ACHMAD TH, RAO GS: Chernotaxis of human blood monocytes toward endothelin-1 and the influence of calcium channel blodcers. Biochem. Biophys. Res. Corn-mun. (1992) 189:994.
   PubMed Web of Science ®Google Scholar
• NAVAS M, HAMA SY, VAN LENTEN BJ, ET AL.: A new anti-inflammatory compound, leumedin, inhibits modifica-tion of low density lipoprotein and the resulting mono-cyte transmigration into the subendothelial space of cocultures of human aortic wall cells. J. Clin. Invest. (1992) 91:1225.
   Google Scholar
• BENNEIT RL, NAVAB M, DEMER LL, FOGELMAN AM: A new anti-inflammatory leucine derivative, NPC-15669, In-hibits growth of cultured human aortic smooth muscle cells. Arteriosclerosis and Thrombosis (1993) 13:360.
   PubMedGoogle Scholar
• DE LA LLERA-MOYA M, ROTHBLAT GH, GLICK JM, ENGL- LAND JM: Etoposide treatment suppresses atherosclerotic plaque development in cholesterol-fed rabbits. Arteriosclerosis and Thrombosis (1992) 12: 1363 .
   PubMedGoogle Scholar
• SINGER AH, TSAO PS, ROWAN R, BILLINGHAM M, COOICE JP: Anti-atherogenic effect of the EDRF precursor. Cir-culation (1992) 86:1–20.
   PubMedGoogle Scholar
• KOWALA MC, MAZZUCCO CE, HARTL KS, ETAL.: Prostacy- clin agonists reduce early atherosclerosis in hyper-lipidemic hamsters. Arteriosclerosis and Thrombosis (1993) 13:435.
   Google Scholar
• FOXALL TL, SHWAERY GT, STUCCHI AF, NICOLOSI RJ, WONG SS: Dose-related effects of doxazosin on plasma lipids and aortic fatty streak formation in the hyper-cholesterolemic hamster modeL Am. J. Patbol. (1992) 140:1357.
   Web of Science ®Google Scholar
• ROLLAND PH, CHARPIOT P, FRIGGI A, ET AL.: Preventive effects of anglotensin converting enzyme inhibition on atherosclerosis-induced changes in haemodynamics and viscoelastic functioning of arterial wall are associ-ated with the preservation of intra-parietal elastic lami-nae and elastin fibres. Circulation (1992) 86:1–157.
   Google Scholar
• TRAVIS J: Novel anticancer agents move closer to reality. Science (1993) 260:1877.
   PubMed Web of Science ®Google Scholar
• SUCKLING KE, JACKSON B: Animal models of human lipid metabolism. Progr. Lpid Res. (1993) 32:1.
   PubMed Web of Science ®Google Scholar
• BORHANI NO, MILLER ST, BRUGGER SB, ET AL,: MIDAS - Hypertension and atherosclerosis - a trial of the effects of antihypertensive drug treatment on atherosclerosis. Cardiovasc. Pbarmacol. (1992) 19:S16.
   Web of Science ®Google Scholar
• ANON: From cardiac to vascular protection: the next chapter. Lancet (1992) 340:1197.
   PubMed Web of Science ®Google Scholar
• DE FEYTER PJ, DIMARIO C, SERRUYS PW, ROELANDT JRTC: How to assess regression of the atherosclerotic plaque.
   Google Scholar
• Biochem. Soc. Transact. (1993) 21:642.
   Google Scholar
• DE FEYTER PJ, SERRUYS PW, DAVIES MJ, ET AL.: Quanti-tative coronary anglography to measure progression and regression of coronary atherosclerosis. Circulation (1991) 84:412.
   Google Scholar
• VOS J, DE FEYTER PJ, SIMOONS ML, T1JSSEN JGP, DECKERS JW: Retardation and arrest of progression or regression of coronary artery disease: A review. Progr. Cardiovasc. Dis. (1993) 35:435.
   PubMed Web of Science ®Google Scholar
• BLANICENHORN DJ, SELZER RH, MACK WJ, ET AL.: Evalu-ation of colestipoliniacin therapy with computer-de-rived coronary endpoint measures. Circulation (1992) 86:1701.
   Google Scholar
• SALONEN JT, SALONEN R: Ultrasound B-mode Imaging in observational studies of atherosclerotic progression. Circulation (1993) 87:11–56.
   Google Scholar
• CROUSE JR: B-mode ultrasound in clinical trials. Circu- lation (1993) 88:319.
   PubMed Web of Science ®Google Scholar
• BLAN10ENHORN DH, SELZER RH, CRAWFORD DW, ET AL.: Beneficial effects of colestipol-niacin therapy on the common carotid artery. Circulation (1993) 88:20.
   Google Scholar
• ST GOAR FG, PINTO FJ, ALDERMAN EL, ET AL.: Detection of coronary atherosclerosis in young adult hearts using intravascular ultrasound. Circulation (1992) 86:756.
   Google Scholar
• WAILER BF, PINKERTON CA, SLACK JD: Intravascular ultrasound: A histological study of vessels during life. Circulation (1992) 85:2305.
   PubMed Web of Science ®Google Scholar
• LASSETTER JE, KRALL RC, MODDRELLE DS, JENKINS RD: Morphologic changes of the arterial wall during regres-sion of experimental atherosclerosis. Circulation (1992) 86:1–518.
   PubMedGoogle Scholar
• NAKATANI S, YAMAGISHI M, TAMAI J, ET AL.: Quantitative assessment of coronary artery stenosis by intravascular Doppler catheter technique. Circulation (1992) 85:1786.
   Google Scholar
• XU Q, WILLEIT J, MAROSI M, ET AL.: Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet (1993) 341:255.
   Google Scholar
• NIKKAR1 ST, SOLAKIVI T, SISTO T, JAAICKOLA O: Antibod- ies to cytoskeletal proteins in sera of patients with anglographically assessed coronary artery disease. Atherosclerosis (1993) 98:11.
   PubMedGoogle Scholar
• TAKASU J, TAKANASHI K, NAITO S, ET AL.: Evaluation of morphological changes of the atherosclerotic aorta by enhanced computed tomography. Atherosclerosis (1992) 97:107.
   Google Scholar
• MEGN1EN JL, SENE V, JEANNIN S, ET AL: Coronary calci- fication and its relation to extracoronary atherosclerosis in asymptomatic hypercholesterolemic men. Circulation (1992) 85:1799.
   PubMed Web of Science ®Google Scholar
• LONGMORE D: Medicine after Hippocrates. Science in Parliament (1992) 49:4.
   Google Scholar
• MANNING INJ, LI W, EDELMAN RR: A preliminary report comparing magnetic resonance coronary angiography with conventional angiography. New Engl. J. Med. (1993) 328:828.
   PubMed Web of Science ®Google Scholar
• EGASHIRA K, INOU T, HIROOKA Y, ET AL.: Impaired coronary blood flow response to acetylcholine in pa-tients with coronary risk factors and proximal atherosclerotic lesions. J. CBI; . Invest. (1993) 91:29.
   Google Scholar
• NARULA J, DITLOW C, CHEN F, STRAUS 1-1W, 1CHAW BA: Non-invasive localization of experimental atherosclerotic lesions with murine/human chimeric antibody Z2D3F(abl2 Circulation (1992) 86:1–709.
   Google Scholar
• HARDOFF R, ZANZONICO P, BRAEGELMANN F, ET AL.: Autoradiographic identification of atherosclerosis with 1–125 SP4. Circulation (1992) 86:1–708.
   Google Scholar
• SONA A, JORI G: Targeting of experimentally-induced atherosderotic lesions by liposome-delivered Zn phthalocyanine. Atherosclerosis (1993) 100:213.
   PubMed Web of Science ®Google Scholar
• WATERS D, CRAVEN TE, LESPERANCE J: Prognostic sig- nificance of progression of coronary atherosclerosis. Circulation (1993) 87:1067.
   PubMed Web of Science ®Google Scholar
• RANICE C, HECICER H, CREUTZIG A ALEXANDER K: Dose- dependent effect of aspirin on carotid atherosclerosis. Circulation (1993) 87:1873.
   PubMedGoogle Scholar
• DREXLER H, ZEIHER AM, KOSthR W, ZEH W, WIELAND H: Endothelial dysfunction in the coronary circulation in hypercholesterolemia. Circulation (1992) 86:1–117.
   PubMedGoogle Scholar
• LEUNG WH, lAU CP, WONG CK: Beneficial effect of cholesterol-lowering therapy on coronary endothe-lium-dependent relaxation in hypercholesterolaemic patients. Lancet (1993) 341:1496.
   PubMed Web of Science ®Google Scholar
• CHOWIENCZYK PJ, WATTS GF, COCKCRAFT JR RTTTER JM: Impaired endothelium-dependent vasodliation of fore-arm resistance vessels in hypercholesterolaemia. Lan-cet (1992) 340:1430.
   PubMed Web of Science ®Google Scholar
• LEES RS: Cholesterol lowering regimens and atherosclerotic disease: Methodological considera-tions. In: Atherosclerosis and Drug Development for Ischae-mic Heart Disease Borer J (Ed), J. Clin. Pharmacol. (1992) 32:848.
   Google Scholar
• FERNS GAA, FORSTER L, STEWART-LEE A, ETAL.: ProbucolInhibits neointimal thickening and macrophage accu-mulation after balloon injury in the cholesterol-fed rabbit. Proc. Natl. Acad. Sci, USA (1992) 89:11312.
   Google Scholar
• FEARS R, ESMAM A, WALKER P, RUSH WR, FERRES H: Hyperalphalipoproteinaemic activity of BRL 26314-H Inhibition of atherosclerosis in rabbits. Biochem. Phar-macol. (1984) 33.
   Google Scholar
• THOMPSON D, OSTER G: Cost-effectiveness of drug therapy for hypercholesterolaemia. PharmacoE-conomics (1992) 2:34.
   PubMedGoogle Scholar
• TOBERT JA: Blood cholesterol measurement in young adults. J. Am. Med. Assoc., (1993) 270:936.
   Google Scholar
• HULLEY SB, NEWMAN TB, GRADY D, ET AL.: Blood cho-lesterol measurement in young adults: Reply./ Am. Med. Assoc. (1993) 270:937.
   Google Scholar